Bayer HealthCare plans a $100 million investment at its manufacturing site in Berkeley, California. The company will build a product testing facility that will support the next generation of treatments for patients with hemophilia A.
According to the firm, its investment represents the company's dedication to science and innovation in the life sciences. The Bay Area is the U.S. headquarters for research, development and biotech manufacturing for Bayer HealthCare.
"The new product testing facility will test Bayer's investigational products in accordance with rigorous global regulatory requirements," said David Weinreich, MD, Head, Global Development, Specialty Medicine at Bayer. "With today's announcement, we are thrilled to further strengthen our commitment to the hemophilia A patient community that Bayer has served for more than a quarter century."
"Building upon our legacy in hemophilia A, we are delighted to continue Bayer's leadership in working to bring treatment options to patients around the world," said Joerg Heidrich, Senior Vice President for Product Supply Biotech and Site Head at Bayer Berkeley. "As the Bay Area's third largest biotech employer, we are also proud to be making this contribution to the world's richest center of biotech R&D, investment, and production."